Results 111 to 120 of about 13,694,185 (310)

Defining Roles in Pediatric Palliative Care: Perspectives From Oncology and Palliative Care Teams

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Early integration of pediatric palliative care (PPC) is associated with improved symptom management, quality of life, and healthcare utilization for children with cancer. Despite this, variation persists in how PPC is understood, operationalized, and integrated within pediatric oncology programs. In particular, ambiguity surrounding
Leeat Granek   +13 more
wiley   +1 more source

Feasibility and Preliminary Efficacy of Integrative Neuromuscular Training for Childhood Cancer Survivors: A Pilot Study

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Survivors of childhood acute lymphoblastic leukemia (ALL) often exhibit early deficits in muscle and movement competence, which can compromise long‐term health. Integrative neuromuscular training (INT), a multifaceted approach combining fundamental movement activities with strength exercises, may help address these deficits during ...
Anna Maria Markarian   +7 more
wiley   +1 more source

The Role of Invasive Procedures in the Treatment of Complicated Gastrointestinal Graft‐Versus‐Host Disease in Pediatric Patients

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Gastrointestinal graft‐versus‐host disease (GI GVHD) following hematopoietic stem cell transplant is typically managed with medical therapy, but surgery and angioembolization may be warranted in selected cases with life‐threatening complications.
Gaia Brunetti   +12 more
wiley   +1 more source

Two Faces of NOTCH1 in Childhood Lymphoblastic T‐Cell Neoplasia: Prognostic Divergence of Mutational and Structural Aberrations

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT In pediatric patients, T‐cell lymphoblastic lymphoma (T‐LBL) survival exceeds 80%. Relapse remains associated with limited curative options. Frontline treatment is largely extrapolated from T‐cell acute lymphoblastic leukemia (T‐ALL) treatment, reflecting the ongoing debate, whether both entities represent distinct diseases or variants within ...
Marie C. Heider   +4 more
wiley   +1 more source

Data Fit for Health Equity: Learning Health Systems, AI, and the STANDING Together Recommendations

open access: yesLearning Health Systems
Introduction Artificial Intelligence (AI) tools may deliver significant improvements in healthcare and Learning Health Systems are well positioned to benefit.
Elinor Laws, Neil Cockburn
doaj   +1 more source

IoMT and Blockchain Synergy: A Novel Approach to Health Data Validation and Storage

open access: yesIEEE Access
The increasing adoption of Internet of Medical Things (IoMT) devices is revolutionizing healthcare, facilitating enhanced remote patient monitoring and data-driven clinical decision-making.
Abbas Syed Muhammad Ali   +4 more
doaj   +1 more source

Blinatumomab Utilization in Pediatric B‐Cell Acute Lymphoblastic Leukemia: Experience From the Mountain West

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Blinatumomab is a bispecific T‐cell engager approved for the treatment of pediatric B‐cell acute lymphoblastic leukemia (B‐ALL). Outpatient home infusion reduces hospitalization burden and optimizes resource utilization, but is logistically challenging.
Angela Parra del Riego   +10 more
wiley   +1 more source

Health data sharing in Germany: individual preconditions, trust and motives

open access: yesFrontiers in Public Health
ObjectiveThe use of health data plays an important role in medical research. In Germany, the secondary use of health data is not yet as established as in other countries.
Elias Kühnel, Felix Wilke
doaj   +1 more source

Ethnic Differences in the Association Between SOD2 rs4880 and Hepatotoxicity in Pediatric Acute Lymphoblastic Leukemia: A Report From the REDIAL Consortium

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Treatment‐associated hepatotoxicity (TAH) is a common complication of pediatric acute lymphoblastic leukemia (ALL) treatment, but genetic risk factors remain poorly understood. We evaluated the SOD2 rs4880 variant in 544 children with ALL at Texas Children's Hospital. After adjusting for demographic and clinical covariates, the rs4880 C allele
Emily J. Mason   +14 more
wiley   +1 more source

Home - About - Disclaimer - Privacy